title: Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets.
abstract: BACKGROUND
  Collectively, research on the role of B-cells in the pathogenesis of multiple sclerosis (MS) illustrates how translational medicine has given rise to promising therapeutic approaches for one of the most debilitating chronic neurological diseases in young adults. First described in 1935, the experimental autoimmune/allergic encephalomyelitis model is a key animal model that has provided the foundation for important developments in targeted therapeutics.
  
  
  CONCLUSIONS
  While additional B-cell therapies for MS are presently being developed by the pharmaceutical industry, much remains to be understood about the role played by B-cells in MS. The goal of this review is to summarize how B-cells may contribute to MS pathogenesis and thereby provide a basis for understanding why B-cell depletion is so effective in the treatment of this disease. Key Messages: B-cells are key players in the pathogenesis of MS, and their depletion via B-cell-targeted therapy ameliorates disease activity.
  
  
  CONCLUSIONS
  In 2008, data from the first CD20-targeting B-cell depleting therapeutic trials using rituximab in MS were published. Since then, there has been a large body of evidence demonstrating the effectiveness of B-cell depletion mediated via anti-CD20 antibodies. Intense research efforts focusing on the immunopathological relevance of B-cells has gained significant momentum and given rise to a constellation of promising therapeutic agents for this complex B-cell-driven disease, including novel anti-CD20 antibodies, as well as agents targeting CD19 and BAFF-R.
authors.forename: H-Christian
authors.initials: HC
authors.lastname: von Büdingen
authors.forename: Arumugam
authors.initials: A
authors.lastname: Palanichamy
authors.forename: Klaus
authors.initials: K
authors.lastname: Lehmann-Horn
authors.forename: Brady A
authors.initials: BA
authors.lastname: Michel
authors.forename: Scott S
authors.initials: SS
authors.lastname: Zamvil
mesh_terms: D000328:Adult; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology*; D000069283:Rituximab / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D007155:Immunologic Factors; D000069283:Rituximab
references.citation: J Neuroimmunol. 2010 Jan 25;218(1-2):134-9
references.pmid: 19900722
references.citation: Neurology. 2006 Aug 22;67(4):652-9
references.pmid: 16870812
references.citation: Brain. 2009 May;132(Pt 5):1175-89
references.pmid: 19339255
references.citation: Neurology. 2014 Feb 18;82(7):573-81
references.pmid: 24453078
references.citation: J Immunol. 2003 Sep 1;171(5):2725-33
references.pmid: 12928426
references.citation: Expert Opin Drug Saf. 2011 Sep;10(5):715-26
references.pmid: 21401437
references.citation: Brain. 2014 Oct;137(Pt 10):2703-14
references.pmid: 25060097
references.citation: Immunity. 2010 Jan 29;32(1):129-40
references.pmid: 20079667
references.citation: Sci Transl Med. 2014 Aug 6;6(248):248ra107
references.pmid: 25100741
references.citation: Ann Neurol. 2010 Sep;68(3):369-83
references.pmid: 20641064
references.citation: J Clin Invest. 1998 Sep 1;102(5):1045-50
references.pmid: 9727074
references.citation: Arthritis Rheum. 2006 Aug;54(8):2377-86
references.pmid: 16869000
references.citation: BioDrugs. 2011 Feb 1;25(1):13-25
references.pmid: 21090841
references.citation: Ann Neurol. 2000 Jun;47(6):707-17
references.pmid: 10852536
references.citation: Nat Med. 2008 Jun;14(6):688-93
references.pmid: 18488038
references.citation: J Immunol. 1999 Nov 1;163(9):5133-44
references.pmid: 10528220
references.citation: Lancet. 2008 Oct 25;372(9648):1502-17
references.pmid: 18970977
references.citation: J Neuroimmunol. 2004 Mar;148(1-2):11-23
references.pmid: 14975582
references.citation: J Clin Invest. 2013 Jun;123(6):2737-41
references.pmid: 23676463
references.citation: J Immunol. 1987 Dec 15;139(12):4016-21
references.pmid: 3500978
references.citation: J Immunol. 2001 Nov 15;167(10):5669-77
references.pmid: 11698439
references.citation: Nature. 2010 Sep 30;467(7315):591-5
references.pmid: 20882016
references.citation: Eur J Immunol. 1999 Nov;29(11):3432-9
references.pmid: 10556797
references.citation: Ann Neurol. 2010 Oct;68(4):477-93
references.pmid: 20976767
references.citation: J Pharmacol Exp Ther. 2010 Oct;335(1):213-22
references.pmid: 20605905
references.citation: Arthritis Rheum. 2009 Dec;60(12):3563-71
references.pmid: 19950291
references.citation: Cytometry. 1993;14(2):196-204
references.pmid: 7679964
references.citation: J Neurol Sci. 2011 Jul 15;306(1-2):9-15
references.pmid: 21529843
references.citation: Ther Adv Neurol Disord. 2010 Jul;3(4):205-16
references.pmid: 21179612
references.citation: J Neuroimmunol. 2011 Apr;233(1-2):245-8
references.pmid: 21353315
references.citation: Neurology. 2002 Aug 27;59(4):555-9
references.pmid: 12196648
references.citation: Neurology. 2000 Mar 28;54(6):1227-32
references.pmid: 10746589
references.citation: Sci Transl Med. 2014 Aug 6;6(248):248ra106
references.pmid: 25100740
references.citation: Arthritis Rheum. 2005 Dec;52(12):3943-54
references.pmid: 16320342
references.citation: Brain. 2002 May;125(Pt 5):952-60
references.pmid: 11960885
references.citation: J Neuroimmunol. 1992 Oct;40(2-3):219-24
references.pmid: 1385471
references.citation: Nature. 2012 Nov 8;491(7423):264-8
references.pmid: 23064231
references.citation: J Clin Invest. 2004 Jul;114(2):280-90
references.pmid: 15254595
references.citation: N Engl J Med. 2008 Feb 14;358(7):676-88
references.pmid: 18272891
references.citation: J Neuroimmunol. 2006 Nov;180(1-2):63-70
references.pmid: 16904756
references.citation: Arthritis Res Ther. 2011;13(6):R208
references.pmid: 22171710
references.citation: Brain. 2010 Feb;133(Pt 2):349-61
references.pmid: 20047900
references.citation: Ann Neurol. 2008 Mar;63(3):395-400
references.pmid: 18383069
references.citation: Ann Neurol. 2014 Feb;75(2):266-76
references.pmid: 24375699
references.citation: J Immunol. 2014 Jul 15;193(2):580-6
references.pmid: 24928997
references.citation: Nat Rev Rheumatol. 2009 Oct;5(10):572-7
references.pmid: 19798033
references.citation: J Immunol. 2005 Jan 15;174(2):817-26
references.pmid: 15634903
references.citation: Eur J Immunol. 2010 Oct;40(10):2942-56
references.pmid: 20812237
references.citation: Neuron. 2006 Oct 5;52(1):61-76
references.pmid: 17015227
references.citation: J Autoimmun. 2011 Dec;37(4):289-99
references.pmid: 21924866
references.citation: Brain. 2006 Jan;129(Pt 1):200-11
references.pmid: 16280350
references.citation: J Exp Med. 2013 Dec 16;210(13):2921-37
references.pmid: 24323356
references.citation: Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15178-83
references.pmid: 16217038
references.citation: Brain Pathol. 2004 Apr;14(2):164-74
references.pmid: 15193029
references.citation: Lancet. 2011 Nov 19;378(9805):1779-87
references.pmid: 22047971
references.citation: Science. 2003 Sep 5;301(5638):1374-7
references.pmid: 12920303
references.citation: Blood. 2011 Jan 13;117(2):530-41
references.pmid: 20962324
references.citation: Scand J Immunol. 1975;4(8):831-6
references.pmid: 1082635
references.citation: Arch Neurol. 1987 Oct;44(10):1041-4
references.pmid: 3632376
references.citation: J Neuroinflammation. 2011;8:146
references.pmid: 22027448
references.citation: J Exp Med. 2005 Jan 17;201(2):195-200
references.pmid: 15642740
references.citation: J Immunol. 2004 Jul 1;173(1):649-56
references.pmid: 15210828
references.citation: J Clin Invest. 1995 Dec;96(6):2966-74
references.pmid: 8675668
references.citation: Brain. 2005 Jul;128(Pt 7):1667-76
references.pmid: 15800022
references.citation: J Immunol. 2000 Mar 1;164(5):2782-9
references.pmid: 10679121
references.citation: J Clin Invest. 2008 Oct;118(10):3420-30
references.pmid: 18802481
references.citation: Nature. 2011 Nov 24;479(7374):538-41
references.pmid: 22031325
references.citation: Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11064-9
references.pmid: 15263096
references.citation: Ann Neurol. 2010 Apr;67(4):452-61
references.pmid: 20437580
references.citation: J Clin Invest. 2012 Dec;122(12):4533-43
references.pmid: 23160197
references.citation: J Immunol. 2004 Aug 15;173(4):2245-52
references.pmid: 15294936
references.citation: J Neurol Sci. 1994 Jul;124(2):215-9
references.pmid: 7964874
references.citation: Arthritis Rheum. 2006 Feb;54(2):613-20
references.pmid: 16447239
references.citation: Lancet Neurol. 2006 Nov;5(11):932-6
references.pmid: 17052660
references.citation: J Immunol. 2004 Jul 15;173(2):807-17
references.pmid: 15240667
references.citation: J Exp Med. 2012 May 7;209(5):1001-10
references.pmid: 22547654
references.citation: Brain. 2011 Feb;134(Pt 2):534-41
references.pmid: 21216828
references.citation: J Autoimmun. 2005 Dec;25(4):298-302
references.pmid: 16242914
references.citation: Brain. 2011 Sep;134(Pt 9):2755-71
references.pmid: 21840891
references.citation: Eur J Immunol. 2002 Jul;32(7):1905-13
references.pmid: 12115610
references.citation: J Immunol. 2007 May 15;178(10):6092-9
references.pmid: 17475834